Viridian Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Veligrotug (VRDN-001) · Cardiovascular
  Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.
• VRDN-003 · Endocrinology / Immunology
  VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Viridian Therapeutics, Inc. portfolio CI brief
• Viridian Therapeutics, Inc. pipeline updates RSS